Francois Cornelis MD, Abstract Co-Author: Nothing to Disclose

Pierre Balageas, Presenter: Nothing to Disclose

Xavier Buy MD, Abstract Co-Author: Nothing to Disclose

Marc André, Abstract Co-Author: Nothing to Disclose

Raymond H Oyen MD, Abstract Co-Author: Nothing to Disclose

Juliette Bouffard-Vercelli, Abstract Co-Author: Nothing to Disclose

Alfredo Blandino, Abstract Co-Author: Nothing to Disclose

Julien Auriol, Abstract Co-Author: Nothing to Disclose

Jean-Michel Correas MD, Abstract Co-Author: Advisory Board, Koninklijke Philips Electronics NV Speaker, Bracco Group Investigator, Bracco Group Speaker, SuperSonic Imagine Speaker, General Electric Company

Pluvinage Amelie, Abstract Co-Author: Nothing to Disclose

Simon Freeman, Abstract Co-Author: Nothing to Disclose

Stephen Barnett Solomon MD, Abstract Co-Author: Advisory Board, General Electric Company Advisory Board, AngioDynamics, Inc Advisory Board, Johnson & Johnson

Nicolas Grenier MD, Abstract Co-Author: Nothing to Disclose

To retrospectively evaluate the medium term outcome of patients treated for primary renal cell carcinomas arising in transplant kidneys with mini-invasive techniques.

The institutional review board of each institution approved this retrospective study and waived informed consent. A web-based call through the European Society of Urogenital Radiology network was made to institutions for patients who fit the requirements outlined by the authors and a prospective follow-up of recipients was performed. We identified 24 tumors, that developed within the renal allograft of 20 transplanted patients from 11 institutions who were treated with radiofrequency (n=19) or cryo (n=5) ablation between 2003 and 2010. Maximal diameter of masses was 6 to 40 mm (median 20 mm). Twenty masses were solid and 4 were type 4 cystic masses. Pre-ablation biopsy was performed for solid tumors only. All images, biological and biopsy reports have been retrospectively reviewed. Statistical significance was calculated using a paired t-test before and after ablation.

Mean follow-up was 27.9 months (7-64 months). Histology revealed 17 papillary and 3 clear cell carcinoma. All tumors were successfully treated under ultrasound guidance in 6 patients, under computed tomography guidance in 10 and under both in 4. One case of infection of the tumor site and one case of transitory genitofemoral nerve injury were the only reported complications. No significant change of renal function was noted. Subsequent imaging follow-up did not reveal any case of recurrence in the ablative site.

Percutaneous thermal ablation of renal tumors occurring in renal grafts is effective with low morbidity.

Thermal ablations are effective in treating renal cell carcinoma occurring in renal allografts. These procedures are well-tolerated and should be considered as an alternative to conventional surgery.

Cornelis, F, Balageas, P, Buy, X, André, M, Oyen, R, Bouffard-Vercelli, J, Blandino, A, Auriol, J, Correas, J, Amelie, P, Freeman, S, Solomon, S, Grenier, N, De Novo Renal Tumors Arising in Kidney Transplants: Midterm Outcomes after Percutaneous Thermal Ablation.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11014378.html